DK3235824T3 - Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat - Google Patents

Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat Download PDF

Info

Publication number: DK3235824T3
Authority: DK; Denmark
Prior art keywords: gemcitabin; alaninyl; benzyloxy; phenyl; phosphate
Prior art date: 2012-11-16

Application number

DK17169878.0T

Other languages

English (en)

Inventor

Christopher Mcguigan

Fabrizio Pertusati

Original Assignee

Univ College Cardiff Consultants Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-16

Filing date

2013-11-15

Publication date

2019-05-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3235824(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-11-16 Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en

2013-04-23 Priority claimed from GB201307314A external-priority patent/GB201307314D0/en

2013-11-15 Application filed by Univ College Cardiff Consultants Ltd filed Critical Univ College Cardiff Consultants Ltd

2019-05-20 Application granted granted Critical

2019-05-20 Publication of DK3235824T3 publication Critical patent/DK3235824T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/06—Halogens; Compounds thereof
- B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
- H01S5/00—Semiconductor lasers
- H01S5/30—Structure or shape of the active region; Materials used for the active region
- H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
- H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
- H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Nanotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Crystallography & Structural Chemistry (AREA)
Biophysics (AREA)
Materials Engineering (AREA)
Tropical Medicine & Parasitology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Endocrinology (AREA)
AIDS & HIV (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Catalysts (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)

DK17169878.0T 2012-11-16 2013-11-15 Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat DK3235824T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1220666.0A GB201220666D0 (en)	2012-11-16	2012-11-16	Process for preparing chemical compounds
GB201307314A GB201307314D0 (en)	2013-04-23	2013-04-23	Process for preparing chemical compounds
EP16195036.5A EP3150616B1 (en)	2012-11-16	2013-11-15	Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate

Publications (1)

Publication Number	Publication Date
DK3235824T3 true DK3235824T3 (da)	2019-05-20

Family

ID=49622844

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK17169878.0T DK3235824T3 (da)	2012-11-16	2013-11-15	Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat
DK16195036.5T DK3150616T3 (da)	2012-11-16	2013-11-15	Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK16195036.5T DK3150616T3 (da)	2012-11-16	2013-11-15	Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat

Country Status (28)

Country	Link
US (3)	US10005810B2 (da)
EP (3)	EP3235824B1 (da)
JP (5)	JP2016506371A (da)
KR (1)	KR20150103669A (da)
CN (2)	CN111592577A (da)
AU (1)	AU2013346515B2 (da)
CA (1)	CA2891266C (da)
CL (1)	CL2015001307A1 (da)
CY (2)	CY1119161T1 (da)
DK (2)	DK3235824T3 (da)
EA (1)	EA028871B1 (da)
ES (3)	ES2627195T3 (da)
HR (2)	HRP20170791T1 (da)
HU (2)	HUE044605T2 (da)
IL (1)	IL238792A (da)
IN (1)	IN2015DN04090A (da)
LT (2)	LT3235824T (da)
MX (1)	MX374779B (da)
MY (1)	MY176133A (da)
NZ (1)	NZ708177A (da)
PH (1)	PH12015501090B1 (da)
PL (2)	PL3235824T3 (da)
PT (2)	PT3150616T (da)
RS (2)	RS58849B1 (da)
SG (3)	SG11201503750YA (da)
SI (2)	SI3150616T1 (da)
SM (2)	SMT201900341T1 (da)
WO (1)	WO2014076490A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0317009D0 (en)	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
RS58849B1 (sr) *	2012-11-16	2019-07-31	Univ College Cardiff Consultants Ltd	Smeša rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata
US10034893B2 (en)	2013-02-01	2018-07-31	Enanta Pharmaceuticals, Inc.	5, 6-D2 uridine nucleoside/tide derivatives
KR20160099090A (ko) *	2013-11-27	2016-08-19	아이데닉스 파마슈티칼스 엘엘씨	간암의 치료를 위한 뉴클레오티드
CN105153257B (zh) *	2014-06-12	2019-03-05	正大天晴药业集团股份有限公司	索非布韦的制备方法
HRP20230584T1 (hr) *	2014-06-25	2023-09-15	NuCana plc	Prolijekovi gemcitabina
US10117888B2 (en)	2014-06-25	2018-11-06	NuCana plc	Formulation comprising a gemcitabine-prodrug
CN105254694B (zh) *	2014-07-14	2018-11-27	正大天晴药业集团股份有限公司	氘代核苷衍生物
WO2016012781A1 (en)	2014-07-22	2016-01-28	Nucana Biomed Limited	Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
US20170218006A1 (en) *	2014-07-31	2017-08-03	Sandoz Ag	Synthesis of Phosphoramidates
US9675632B2 (en)	2014-08-26	2017-06-13	Enanta Pharmaceuticals, Inc.	Nucleoside and nucleotide derivatives
CN105461773B (zh) *	2014-09-30	2020-12-01	江苏豪森药业集团有限公司	索非布韦的制备方法及其中间体
CN105461774B (zh) *	2014-09-30	2020-11-24	江苏豪森药业集团有限公司	索非布韦的制备方法
GB201417644D0 (en) *	2014-10-06	2014-11-19	Nucana Biomed Ltd	Method of separating phosphate diastereoisomers
WO2016073756A1 (en)	2014-11-06	2016-05-12	Enanta Pharmaceuticals, Inc.	Deuterated nucleoside/tide derivatives
US9732110B2 (en)	2014-12-05	2017-08-15	Enanta Pharmaceuticals, Inc.	Nucleoside and nucleotide derivatives
US9828410B2 (en)	2015-03-06	2017-11-28	Atea Pharmaceuticals, Inc.	β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
EP3274356A1 (en)	2015-03-26	2018-01-31	Química Sintética, S.A.	Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515B (zh) *	2015-07-28	2021-05-11	广东东阳光药业有限公司	一种改良的索菲布韦制备方法
CN106543220A (zh)	2015-09-16	2017-03-29	博瑞生物医药（苏州）股份有限公司	氨基磷酸酯化合物及其制备方法和晶体
CN106539810B (zh) *	2015-09-16	2021-03-09	济南高合医疗科技有限公司	一种富集了nuc-1031单一异构体的组合物及其制备方法和用途
CN106543252A (zh) *	2015-09-16	2017-03-29	博瑞生物医药（苏州）股份有限公司	核苷氨基磷酸酯类前药的制备方法及其中间体
KR20180063075A (ko)	2015-10-05	2018-06-11	뉴카나 피엘씨	조합 요법
WO2017090264A1 (ja) *	2015-11-27	2017-06-01	大原薬品工業株式会社	５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
CN108779136B (zh)	2015-12-11	2022-07-08	努卡那有限公司	磷酸酯衍生物和吉西他滨前药nuc-1031的非对映选择性合成
GB201522771D0 (en) *	2015-12-23	2016-02-03	Nucana Biomed Ltd	Crystalline form of a phosphate derivative
GB201609602D0 (en) *	2016-06-01	2016-07-13	Nucuna Biomed Ltd	Chemical compounds
US10202412B2 (en)	2016-07-08	2019-02-12	Atea Pharmaceuticals, Inc.	β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
LU100724B1 (en)	2016-07-14	2018-07-31	Atea Pharmaceuticals Inc	Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) *	2016-07-20	2019-03-26	Optimus Drugs (P) Limited	Process for the preparation of sofosbuvir
WO2018019188A1 (zh) *	2016-07-23	2018-02-01	博瑞生物医药（苏州）股份有限公司	核苷氨基磷酸酯类前药的多晶型及其制备方法
EP4088725A1 (en)	2016-09-07	2022-11-16	ATEA Pharmaceuticals, Inc.	2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family
US10266558B2 (en) *	2016-10-07	2019-04-23	Alexandre Vasilievich Ivachtchenko	Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
CA3041423A1 (en) *	2016-12-23	2018-06-28	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Nucleoside phosphate compound and preparation method and use thereof
HRP20250266T1 (hr)	2017-02-01	2025-04-25	Atea Pharmaceuticals, Inc.	Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c
GB201709471D0 (en)	2017-06-14	2017-07-26	Nucana Biomed Ltd	Diastereoselective synthesis of hosphate derivatives
JP2021521118A (ja)	2018-04-10	2021-08-26	アテアファーマシューティカルズ，インコーポレイテッド	肝硬変を伴うｈｃｖ感染患者の治療
WO2019237957A1 (zh)	2018-06-12	2019-12-19	四川科伦博泰生物医药股份有限公司	膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
US10874687B1 (en)	2020-02-27	2020-12-29	Atea Pharmaceuticals, Inc.	Highly active compounds against COVID-19
RU2740058C1 (ru) *	2020-06-26	2020-12-31	Общество С Ограниченной Ответственностью "Технология Лекарств"	Способ получения софосбувира и фосфорамидаты
CN112409431B (zh) *	2020-12-07	2023-04-21	武汉伯瑞恒医药科技有限公司	阿糖胞苷结构类似物及其制备方法和用途
EP4355319A4 (en)	2021-06-17	2025-01-22	ATEA Pharmaceuticals, Inc.	BENEFICIAL ANTI-HCV COMBINATION THERAPY
CN113549076B (zh) *	2021-07-23	2022-12-06	中国药科大学	一种多取代嘌呤类化合物及其制备方法和应用
WO2024107859A1 (en) *	2022-11-15	2024-05-23	Rome Therapeutics, Inc.	Cyclopentene-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5827727A (en)	1990-02-01	1998-10-27	Emory University	Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) *	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en)	1990-02-01	2004-03-09	Emory University	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
WO1999037753A1 (en)	1998-01-23	1999-07-29	Newbiotics, Inc.	Enzyme catalyzed therapeutic agents
US7462605B2 (en)	1998-01-23	2008-12-09	Celmed Oncology (Usa), Inc.	Phosphoramidate compounds and methods of use
JP2005522443A (ja)	2002-02-14	2005-07-28	フアーマセツト・リミテツド	改変フッ素化ヌクレオシド類似体
WO2004041203A2 (en)	2002-11-04	2004-05-21	Xenoport, Inc.	Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
GB0317009D0 (en) *	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
GB0505781D0 (en) *	2005-03-21	2005-04-27	Univ Cardiff	Chemical compounds
CA2618335C (en) *	2005-08-15	2015-03-31	F.Hoffmann-La Roche Ag	Antiviral phosphoramidates of 4'-substituted pronucleotides
GB0623493D0 (en) *	2006-11-24	2007-01-03	Univ Cardiff	Chemical compounds
US7964580B2 (en) *	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) *	2008-12-08	2010-07-27	Medivir Ab	Nucleótidos uracil ciclopropílicos
WO2010081082A2 (en) *	2009-01-09	2010-07-15	University College Of Cardiff Consultants Limited	Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
TWI598358B (zh) *	2009-05-20	2017-09-11	基利法瑪席特有限責任公司	核苷磷醯胺
EP2609923B1 (en)	2010-03-31	2017-05-24	Gilead Pharmasset LLC	Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
US9090642B2 (en) *	2010-07-19	2015-07-28	Gilead Sciences, Inc.	Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
CN103209987B (zh) *	2010-09-22	2017-06-06	艾丽奥斯生物制药有限公司	取代的核苷酸类似物
CA2819041A1 (en) *	2010-12-22	2012-06-28	Alios Biopharma, Inc.	Cyclic nucleotide analogs
PT3447061T (pt) *	2011-03-01	2021-12-23	NuCana plc	Formulação farmacêutica que compreende um derivado de fosforamidato de 5-fluoro-2¿-desoxiuridina para utilização no tratamento de cancro
EP2680859B1 (en) *	2011-03-02	2022-04-27	Jerome Schentag	Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
SG11201401499XA (en) *	2011-10-14	2014-09-26	Stc Unm	Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
RS58849B1 (sr)	2012-11-16	2019-07-31	Univ College Cardiff Consultants Ltd	Smeša rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata
TW201542578A (zh) *	2013-06-26	2015-11-16	Alios Biopharma Inc	經取代之核苷、核苷酸及其類似物
PL3043803T3 (pl)	2013-09-11	2022-11-07	Emory University	Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
PE20160658A1 (es) *	2013-10-11	2016-08-05	Alios Biopharma Inc	Nucleosidos sustituidos, nucleotidos y analogos de los mismos
KR20160099090A (ko)	2013-11-27	2016-08-19	아이데닉스 파마슈티칼스 엘엘씨	간암의 치료를 위한 뉴클레오티드
WO2015080949A1 (en) *	2013-11-27	2015-06-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Piperidine and piperazine derivatives and their use in treating viral infections and cancer
HRP20230584T1 (hr)	2014-06-25	2023-09-15	NuCana plc	Prolijekovi gemcitabina
US10117888B2 (en)	2014-06-25	2018-11-06	NuCana plc	Formulation comprising a gemcitabine-prodrug
WO2016012781A1 (en)	2014-07-22	2016-01-28	Nucana Biomed Limited	Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
GB201417644D0 (en)	2014-10-06	2014-11-19	Nucana Biomed Ltd	Method of separating phosphate diastereoisomers
SMT201800303T1 (it)	2015-05-14	2018-07-17	NuCana plc	Trattamenti per il cancro
KR20180063075A (ko)	2015-10-05	2018-06-11	뉴카나 피엘씨	조합 요법
CN108779136B (zh)	2015-12-11	2022-07-08	努卡那有限公司	磷酸酯衍生物和吉西他滨前药nuc-1031的非对映选择性合成
MX383988B (es)	2015-12-23	2025-03-14	NuCana plc	Terapia de combinación.
GB201522771D0 (en)	2015-12-23	2016-02-03	Nucana Biomed Ltd	Crystalline form of a phosphate derivative
US20190381084A1 (en)	2015-12-23	2019-12-19	Nucana Biomed Limited	Combination therapy
GB201713914D0 (en)	2017-08-30	2017-10-11	Nucana Biomed Ltd	Combination therapy
JP2020171815A (ja) *	2020-07-29	2020-10-22	株式会社ユニバーサルエンターテインメント	プログラム

2013
- 2013-11-15 RS RS20190549A patent/RS58849B1/sr unknown
- 2013-11-15 AU AU2013346515A patent/AU2013346515B2/en not_active Ceased
- 2013-11-15 EA EA201590955A patent/EA028871B1/ru unknown
- 2013-11-15 IN IN4090DEN2015 patent/IN2015DN04090A/en unknown
- 2013-11-15 SG SG11201503750YA patent/SG11201503750YA/en unknown
- 2013-11-15 KR KR1020157015861A patent/KR20150103669A/ko not_active Ceased
- 2013-11-15 PL PL17169878T patent/PL3235824T3/pl unknown
- 2013-11-15 DK DK17169878.0T patent/DK3235824T3/da active
- 2013-11-15 SM SM20190341T patent/SMT201900341T1/it unknown
- 2013-11-15 ES ES16195036.5T patent/ES2627195T3/es active Active
- 2013-11-15 HU HUE17169878 patent/HUE044605T2/hu unknown
- 2013-11-15 LT LTEP17169878.0T patent/LT3235824T/lt unknown
- 2013-11-15 WO PCT/GB2013/053018 patent/WO2014076490A1/en not_active Ceased
- 2013-11-15 PT PT161950365T patent/PT3150616T/pt unknown
- 2013-11-15 SM SM20170349T patent/SMT201700349T1/it unknown
- 2013-11-15 EP EP17169878.0A patent/EP3235824B1/en active Active
- 2013-11-15 PT PT17169878T patent/PT3235824T/pt unknown
- 2013-11-15 HU HUE16195036A patent/HUE033335T2/en unknown
- 2013-11-15 SG SG10201510324YA patent/SG10201510324YA/en unknown
- 2013-11-15 SI SI201330652T patent/SI3150616T1/sl unknown
- 2013-11-15 PL PL16195036T patent/PL3150616T3/pl unknown
- 2013-11-15 MY MYPI2015001314A patent/MY176133A/en unknown
- 2013-11-15 JP JP2015542357A patent/JP2016506371A/ja active Pending
- 2013-11-15 CA CA2891266A patent/CA2891266C/en active Active
- 2013-11-15 EP EP13792965.9A patent/EP2920192B1/en not_active Not-in-force
- 2013-11-15 NZ NZ708177A patent/NZ708177A/en not_active IP Right Cessation
- 2013-11-15 ES ES13792965.9T patent/ES2618732T3/es active Active
- 2013-11-15 CN CN202010526209.7A patent/CN111592577A/zh active Pending
- 2013-11-15 CN CN201380069952.2A patent/CN104903339A/zh active Pending
- 2013-11-15 DK DK16195036.5T patent/DK3150616T3/da active
- 2013-11-15 ES ES17169878T patent/ES2725491T3/es active Active
- 2013-11-15 EP EP16195036.5A patent/EP3150616B1/en active Active
- 2013-11-15 LT LTEP16195036.5T patent/LT3150616T/lt unknown
- 2013-11-15 SI SI201331437T patent/SI3235824T1/sl unknown
- 2013-11-15 US US14/442,987 patent/US10005810B2/en active Active
- 2013-11-15 MX MX2015006195A patent/MX374779B/es active IP Right Grant
- 2013-11-15 RS RS20170506A patent/RS56038B1/sr unknown
- 2013-11-15 SG SG10201510322UA patent/SG10201510322UA/en unknown
2015
- 2015-05-13 IL IL238792A patent/IL238792A/en active IP Right Grant
- 2015-05-14 CL CL2015001307A patent/CL2015001307A1/es unknown
- 2015-05-15 PH PH12015501090A patent/PH12015501090B1/en unknown
2017
- 2017-05-24 CY CY20171100539T patent/CY1119161T1/el unknown
- 2017-05-29 HR HRP20170791TT patent/HRP20170791T1/hr unknown
- 2017-08-10 JP JP2017154931A patent/JP2018009000A/ja not_active Withdrawn
2018
- 2018-05-31 US US15/994,378 patent/US11040997B2/en active Active
2019
- 2019-05-06 HR HRP20190831TT patent/HRP20190831T1/hr unknown
- 2019-05-09 CY CY20191100503T patent/CY1121663T1/el unknown
- 2019-06-18 JP JP2019112739A patent/JP2019196360A/ja active Pending
2020
- 2020-10-12 JP JP2020171815A patent/JP7519259B2/ja active Active
2021
- 2021-05-18 US US17/323,367 patent/US20220033433A1/en not_active Abandoned
2023
- 2023-01-20 JP JP2023007007A patent/JP2023052536A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DK3150616T3 (da)	2017-06-06
SG11201503750YA (en)	2015-06-29
LT3150616T (lt)	2017-07-25
EP2920192A1 (en)	2015-09-23
PL3235824T3 (pl)	2019-09-30
IL238792A (en)	2017-09-28
JP2021020919A (ja)	2021-02-18
PT3150616T (pt)	2017-06-09
HRP20190831T1 (hr)	2019-08-23
US20180273575A1 (en)	2018-09-27
HUE033335T2 (en)	2017-11-28
PL3150616T3 (pl)	2017-09-29
JP2019196360A (ja)	2019-11-14
NZ708177A (en)	2017-08-25
MX2015006195A (es)	2015-12-08
MX374779B (es)	2025-03-06
BR112015011155A2 (pt)	2017-07-11
CN111592577A (zh)	2020-08-28
JP2018009000A (ja)	2018-01-18
AU2013346515B2 (en)	2017-05-25
HUE044605T2 (hu)	2019-11-28
HK1210784A1 (en)	2016-05-06
RS58849B1 (sr)	2019-07-31
ES2725491T3 (es)	2019-09-24
PT3235824T (pt)	2019-05-30
EP3235824A1 (en)	2017-10-25
SMT201700349T1 (it)	2017-09-07
IN2015DN04090A (da)	2015-10-09
HRP20170791T1 (hr)	2017-08-25
KR20150103669A (ko)	2015-09-11
CA2891266C (en)	2020-12-08
CY1119161T1 (el)	2018-02-14
MY176133A (en)	2020-07-24
PH12015501090B1 (en)	2019-01-30
JP7519259B2 (ja)	2024-07-19
CN104903339A (zh)	2015-09-09
CY1121663T1 (el)	2020-07-31
EP3150616B1 (en)	2017-05-10
SMT201900341T1 (it)	2019-07-11
ES2627195T3 (es)	2017-07-27
RS56038B1 (sr)	2017-09-29
PH12015501090A1 (en)	2015-07-27
JP2023052536A (ja)	2023-04-11
EP3150616A1 (en)	2017-04-05
SI3150616T1 (sl)	2017-08-31
EA201590955A1 (ru)	2015-08-31
SG10201510322UA (en)	2016-01-28
US11040997B2 (en)	2021-06-22
US20220033433A1 (en)	2022-02-03
US10005810B2 (en)	2018-06-26
SG10201510324YA (en)	2016-01-28
EP2920192B1 (en)	2017-02-22
JP2016506371A (ja)	2016-03-03
SI3235824T1 (sl)	2019-08-30
LT3235824T (lt)	2019-07-10
CL2015001307A1 (es)	2015-12-11
EP3235824B1 (en)	2019-03-27
US20150291650A1 (en)	2015-10-15
ES2618732T3 (es)	2017-06-22
WO2014076490A1 (en)	2014-05-22
EA028871B1 (ru)	2018-01-31
AU2013346515A1 (en)	2015-06-04
IL238792A0 (en)	2015-06-30
CA2891266A1 (en)	2014-05-22

Publication	Publication Date	Title
DK3235824T3 (da)	2019-05-20	Blanding af rp/sp gemcitabin-[phenyl-(benzyloxy-l-alaninyl)]-phosphat
DK3533792T3 (da)	2021-06-28	Krystallinske former af en androgenreceptormodulator
DK2906696T4 (da)	2023-02-27	Fremgangsmåder til modulering af c9orf72-ekspression
DK2845905T3 (da)	2021-06-14	Fremstilling af oligosaccharider
EP2850106A4 (en)	2016-04-20	BISPECIFIC SCFV IMMUNOFUSION (BIF)
BR302012005260S1 (pt)	2013-10-08	Configuracao aplicada em autoinjetor
BR302012005258S1 (pt)	2013-10-08	Configuracao aplicada em autoinjetor
DK3281664T3 (da)	2021-01-25	Nasale indgivelsesindretninger
EP2979402A4 (en)	2016-11-30	FORWARDING OF PACKAGES
BR302012005259S1 (pt)	2013-10-08	Configuracao aplicada em autoinjetor
DK2981255T3 (da)	2022-11-14	Terapeutiske anvendelser af empagliflozin
LT2869563T (lt)	2018-07-10	Vaizdo entropinio dekodavimo būdas
DK3461895T3 (da)	2020-07-20	Modulation af ube3a-ats-ekspression
HUE042443T2 (hu)	2019-06-28	GPR6 tetrahidropiridopirazin-modulátorai
EP2880905A4 (en)	2015-12-23	AVAILABILITY OF COMMUNICATION MODES
EP2803885A4 (en)	2015-11-11	MIXER
EP2873453A4 (en)	2016-03-23	STIRRERS
SMT201600410B (it)	2017-01-10	Modulatori diidropirazolici di gpr40
DK2822568T3 (da)	2020-08-10	Anvendelser af caseinsammensætninger
DK2965026T3 (da)	2019-10-28	Generering af slushice
EP2945942A4 (en)	2016-08-03	Voriconazole IMMUNOASSAY
DK2854831T3 (da)	2024-10-14	Fremstilling af degarelix
DK2894998T3 (da)	2020-03-02	Rotation af kegle
EP3012307A4 (en)	2016-06-29	MIXED REFRIGERANT
HUE049492T2 (hu)	2020-09-28	Magéleterõ modulálása